Clinical Trials List
2023-12-01 - 2024-12-04
Phase III
Recruiting4
Terminated1
ICD-10D59.0
Drug-induced autoimmune hemolytic anemia
ICD-10D59.1
Other autoimmune hemolytic anemias
ICD-9283.0
Autoimmune hemolytic anemias
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Chien-Chin Lin Division of Hematology & Oncology
- MING YAO Division of Hematology & Oncology
- Wen-Chien Chou Division of Hematology & Oncology
- CHENG-HONG TSAI Division of Hematology & Oncology
- Huai-Hsuan Huang Division of Hematology & Oncology
- - - Division of Hematology & Oncology
- HSIN-AN HOU Division of Hematology & Oncology
- Chieh-Lung Cheng Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 黃文聰 Division of Hematology & Oncology
- 林建良 Division of Hematology & Oncology
- 曹朝榮 Division of Hematology & Oncology
- 陳昭勳 Division of Hematology & Oncology
- 陳彥勳 Division of Hematology & Oncology
- 陳冠宇 Division of Hematology & Oncology
- 高婉真 無
- Shang-Wen Chen Division of Hematology & Oncology
- 林正耀 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Ya-Ping Chen Division of Hematology & Oncology
- Tsai-Yun Chen Division of Hematology & Oncology
- 傅蓓安 Division of Hematology & Oncology
- Sin-Syue Li Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 高婉真 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
5 participants
-
Global
134 participants
